Four integrated symposium sessions, 11 poster presentations, and case studies will cover the clinical value of integrating diagnostic stewardship into current sepsis protocols given the rising rates of antibiotic resistance

TUCSON, Ariz., April 21, 2018 (GLOBE NEWSWIRE) — Accelerate Diagnostics, Inc. today announced the sizeable release of new data presented by the company, its customers, and clinical experts during the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, located in IFEMA – Feria de Madrid, Madrid, Spain, April 21 – 24th.

The symposium presentations on Monday, April 23, 9 – 11 a.m., in Hall L,
will focus on best practices in the management of hospitalized patients with bacteremia using integrating diagnostics, sepsis protocols and antimicrobial stewardship. All presentations will be followed by Q & A sessions.

The first presentation, held 9:05 – 9:25 a.m., “Challenges of Antibiotic Stewardship in the Critically Ill,” will be presented by Professor Jan De Waele of Ghent University, Ghent, Belgium.

The third presentation, held from 9:55 – 10:20 a.m., “Case Studies in Bacteremia, Sepsis and Septic Shock,” will be presented by Dr. Claire Thomas of Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom.

The fourth presentation, held from 10:20 to 10:30 a.m., “Critical Need to Develop Susceptibility Testing Capacity in Clinical Laboratories” will be presented by Dr. Romney Humphries of Accelerate Diagnostics, Tucson, USA.

Recognized as the largest European congress covering its fields, ECCMID is the 28th European Congress of Clinical Microbiology and Infectious Diseases, organized on April 21 and lasting till 24 April 2018 in Madrid, Spain. The congress, hosted by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), is expected to attract more than 12,000 clinical investigators, scientists and medical professionals related to the fields of microbiology and infectious diseases. The congress focuses on sharing and delivering educational sessions on recent advancements in research and clinical experience in the field of infectious diseases, infection control and clinical microbiology.

About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and healthcare-associated infections. The company recently obtained FDA marketing authorization for antimicrobial susceptibility testing direct from positive blood culture samples using its Accelerate PhenoTM system and Accelerate PhenoTestTM BC kit. The system and kit leverage proprietary molecular identification methods and morphokinetic cellular analysis (MCA) to provide minimum inhibitory concentrations for a range of applicable antibiotics. The fully-automated system is designed to eliminate the lengthy culture and sample preparation steps required prior to antimicrobial susceptibility testing. Recent studies suggest the solution offers results 1-2 days faster than conventional methods, enabling clinicians to optimize antibiotic selection, dosage, and infusion strategy specific to the individual patient and their infection.

The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.